Any one watching GNBT. It has been under a lot of dilution

New Post Public Reply Private Reply Replies (0) Message Board
docj
136
Any one watching GNBT. It has been under a lot of dilution sell pressure but the news they put out yesterday looks very promising:


Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key
COVID-19 Vaccine Development Program and
Files Trademark Application for The Complete Vaccine™
− The trademark application can be found at USPTO.gov by searching “Complete Vaccine”
in the Trademark Electronic Search System (TESS)
− Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical supply
− Ii-Key epitopes selected that elicit both CD4+ T Helper cell (Th1) and CD8+ responses
that are necessary for long-term immune memory
− Ii-Key epitopes elicited no Th2 T cell responses that have been linked to antibody
dependent enhancement of disease and cytokine storm
− Ii-Key epitopes have been used to purify Anti-SARS-CoV-2 antibodies from convalescent
COVID-19 patient serum
− Neutralizing antibodies purified with Ii-Key epitopes have potential as a therapeutic
treatment for COVID-19
− Addressing emergence of mutant coronavirus strains
− Exploring new opportunities to utilize Ii-Key-SARS-CoV-2 vaccines as a targeted universal
booster designed to alleviate the immune related side effects reported with the current
RNA vaccines
MIRAMAR, FL, December 31, 2020 - Generex Biotechnology Corporation (www.generex.com)
(OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its
majority owned public entity, NuGenerex Immuno-Oncology, Inc. (NGIO), has filed for and
expects to receive a trademark for The Complete Vaccine™. A complete vaccine is designed to
regulate the immune system to provide a targeted, neutralizing antibody response without
generating off-target, non-neutralizing antibodies that can lead to antibody dependent
enhancement of disease (ADE); further a complete vaccine should activate the appropriate T cell
responses to yield long-term immune memory without activating detrimental Th2 responses that
have been associated with immune-related complications of COVID-19 disease.
Generex also announced that significant progress has been made on the li-Key-SARS-CoV-2
vaccine program. The team at NGIO has completed the T Cell assays and HLA typing of blood
samples from 46 convalescent COVID-19 patients and 30 healthy pre-COVID donors (from 2017
and 2018), screening the immune regulatory activity of 33 Ii-Key epitopes. The results of the T
cell screen demonstrated that numerous Ii-Key epitopes activate CD4+ Th1 and CD8+ responses;
none of the Ii-Key epitopes tested activated any negative Th2 responses.
Additionally, the Ii-Key epitopes have been used to bind and purify IgG antibodies from
convalescent COVID-19 patient samples. These antibodies are being tested against live SARSCoV-2 virus in a level 3 biocontainment laboratory to ensure that they neutralize the virus. Once
confirmed as neutralizing, these Ii-Key epitope binding antibodies can be purified and genetically
engineered to develop antibody therapeutics against COVID-19.
Based on the results of the ex-vivo human studies, Generex has initiated GMP production of
several Ii-Key-SARS-CoV-2 epitopes that will be formulated for Phase I and Phase II clinical trials;
an IND is being prepared for FDA submission in early 2021. With multiple epitopes that are
targeted to generate specific, neutralizing regions of the coronavirus without off-target effects,
and which have demonstrated positive T cell regulation necessary for long-term immune
memory, the Ii-Key COVID-19 vaccine has the potential to be a complete vaccine.
It has been widely reported that the SARS-CoV-2 virus, like all viruses, is mutating. Some of the
mutational variants, with mutations that mainly occur in the virus spike protein, appear to have
biological differences that may alter infectivity, transmission, and severity of infection. The Ii-Key
vaccine platform is built to address issues of mutation. First, there are multiple Ii-Key-SARS-CoV2 peptides, each containing multiple epitopes in the vaccine formulation. So even if there is one
mutation, the other epitopes should provide protection. Second, if a new strain emerges, the IiKey platform can be rapidly deployed to make the new, mutant sequence with Ii-Key and add it
to the current vaccine. This is the beauty of the Ii-Key technology. Further, the epitopes predicted
by computational algorithms exclude regions of the coronavirus that are susceptible to mutation,
so the Ii-Key vaccine largely eliminates mutagenic regions from the start.
With an impending IND submission for Phase I and II human clinical trials to evaluate safety and
immunogenicity of the Ii-Key vaccine, NGIO is exploring additional opportunities to deploy the
targeted Ii-Key COVID-19 vaccine as a universal booster for RNA, DNA, and inactivated virus
vaccines that contain the entire spike protein and have the potential to elicit off-target and overactive immune responses. Recent reports of immune related side effects after booster
inoculation with RNA vaccines include fever, chills, fatigue, and joint pain. These immune related
side effects to the RNA vaccine mimic the immune response to coronavirus infection to provide
immunity to COVID-19 as evidenced by 90+% efficacy rate. However, these strong immune
responses also have the potential to lead to ADE, as has been shown in SARS-1, and questions
remain as to the ability of the RNA vaccines to generate long-term immune memory. The targeted
Ii-Key-SARS-CoV-2 vaccine is designed to generate long-term immune memory through specific
T cell activation by the Ii-Key, and the antibody purification studies demonstrate the potential for
the Ii-Key vaccine to elicit a targeted, neutralizing immune response without off-target effects.
Using a targeted Ii-Key-SARS-CoV-2 vaccine as a universal booster may provide long-term
immunity without causing the immune related side effects from off-target responses. Such a
universal Ii-Key vaccine booster could significantly extend the currently limited supply of RNA
vaccines, and with a clean side effect profile the Ii-Key booster may increase consumer
acceptance.
Generex CEO, Joseph Moscato said, “Throughout this challenging year of 2020, we have
overcome numerous hurdles to reach this point with our Ii-Key COVID-19 vaccine. We have filed
an extensive patent application that covers our Ii-Key-SARS-CoV-2 vaccine and provides the
foundation for a new patent estate for the Ii-Key platform. The results of our ex vivo human
studies have been better than expected, and we have several Ii-Key epitopes that regulate the
immune responses we seek in a vaccine formulation. The antibody data are especially
encouraging. The results confirm that we are targeting immunologically important regions of the
virus and demonstrate the ability to purify neutralizing antibodies from patient serum that can
be developed as a targeted antibody therapeutic against COVID-19.
The Ii-Key vaccine is designed to be a Complete Vaccine, and we believe that our technology
offers the safest and best route for the rapid development of a COVID-19 vaccine that can be
safely administered to everyone, including adolescents, children and pregnant women without
worry of immune related side effects. As we prepare for our first in human studies of the vaccine
in healthy adults, we also plan to include underserved populations with risk factors for COVID19, elderly subjects who are at high risk for serious complications from coronavirus infection, and
working with our SAB, we are planning a focused clinical program for adolescents, children, and
pregnant women.”
Mr. Moscato continued, “On the international front, we are moving forward with our partners in
Malaysia and China on the development of the Ii-Key-SARS-CoV-2 vaccine. Bintai Kinden is
supporting our US development efforts in exchange for exclusive distribution rights in Malaysia
and Southeast Asia. We have also initiated discussions with our Chinese partners on the
technology transfer, GMP production, and regulatory filings with the NMPA for the Phase I, II and
III clinical programs in China. This partnership in China will also enable us to explore the potential
of the Ii-Key-SARS-CoV-2 vaccine as a universal booster.”
“We look forward to an exciting 2021 as we advance the Ii-Key COVID vaccine into the clinic with
the goal of gaining FDA approval for a Complete Vaccine™. On behalf of the Generex and NGIO
management teams, we wish our shareholders and investors a happy, healthy, and prosperous
New Year as we continue to execute our plans to build value for the future.”





Happy New Year!

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Insiders Buy Up on MicroStrategy While Analysts Expect Growth

Updated Category News Views 198

Insider Purchases Indicate Confidence in MicroStrategy Recently, insiders at MicroStrategy Incorporated (NASDAQ: MSTR) have made notable stock purchases that are turning heads in the financial community. Even though there were increases in insider share sales in the last quarter, which reached a two-year peak, the market has not reacted unfavorably. Most of these sales...

Continue Reading
Burlington Stores Insider Transaction: Stephen Ferroni's Move

Updated Category News Views 174

Burlington Stores Insider Transaction Details In a significant move recently disclosed in an SEC filing, Stephen Ferroni, the Senior Vice President at Burlington Stores, made headlines by exercising company stock options. This transaction, involving the exercise of options for 1,123 shares, amounted to a transaction value of approximately $200,331. The filing highlights...

Continue Reading
Clairvest Group's Strategic Acquisition of MGM Northfield Park

Updated Category News Views 371

Clairvest Group Expands Horizons with MGM Northfield Park Acquisition Exciting developments are shaping the landscape for Clairvest Group Inc. as they embark on a significant acquisition journey with MGM Northfield Park. This strategic move not only highlights Clairvest's commitment to growth in the gaming sector but also enhances their longstanding reputation for...

Continue Reading
Innovent Biologics Showcases Promising Research at ADA 85th Sessions

Updated Category News Views 576

Innovent Biologics Presents Cutting-Edge Research at ADA Innovent Biologics, Inc. (HKEX: 01801) has made significant advancements in the biopharmaceutical industry, focusing on innovative treatments for oncology, autoimmune diseases, and metabolic conditions. Recently, the company announced that it will showcase exciting results from its research pipeline at the American...

Continue Reading
Promising Results from HERIZON-GEA-01 Trial Support Ziihera®

Updated Category News Views 288

Encouraging HERIZON-GEA-01 Phase 3 Findings Reinforce Ziihera®’s Role Ziihera, when combined with chemotherapy, has demonstrated a significant improvement in progression-free survival (PFS) compared to trastuzumab and chemotherapy combinations. It also showed a strong trend towards enhancing overall survival (OS) at the first analysis. Clinical Outcomes of Ziihera in...

Continue Reading